echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > A&R: A Safety and Efficacy Study of Bimegizumab in Active Psoriatic Arthritis

    A&R: A Safety and Efficacy Study of Bimegizumab in Active Psoriatic Arthritis

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    OBJECTIVE: To evaluate the long-term safety, tolerability, and efficacy of bimegizumab in the treatment of active psoriatic arthritis (PsA.


    Long-term safety, tolerability, and efficacy of bimegizumab in psoriatic arthritis (PsA )

    METHODS: Adult patients with active PsA who completed the double-blind and dose-blind phases of the BE-active randomized controlled trial could enroll in an open-label extension (OLE) study at week 48 , after which patients received 160 mg of bimegizumab every four wee.


    Open Label Extensions (OLE) Research Open Label Extensions (OLE) Research

    RESULTS: At Week 152, 161/206 patients (72%) remained in the stu.


    Efficacy at 48 weeks was maintained in O.


    100% skin clearance with minimal disease activity

    Conclusions: The safety profile of bimegizumab was consistent with previous reports , and no new safety signals were identified


    Bimegizumab safety profile consistent with previous reports No new safety signals identified

    Source:

    Source:

    Coates LC, McInnes IB, Merola JF, et .


    Coates LC, McInnes IB, Merola JF, et .
    Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study [published online ahead of print, 2022 Jul 1
    Arthritis Rheumat.
    2022;11002/a.
    4228 doi:11002/a.
    42280 Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.